Pfizer Raises 2026 Sales Outlook By $500 Million On Strong Demand For Older Drugs
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Pfizer reported stronger-than-expected earnings for the second quarter of 2026, leading the company to raise the midpoint of its sales forecast. The updated guidance reflects strong demand for older medicines, despite a reduction in revenue expectations for its Covid products, which were cut to $4 billion from around $5 billion.
The increase in sales outlook comes as Pfizer continues to see robust performance from its portfolio, particularly with the drug Eliquis. The company is now projecting higher overall revenue for the year, indicating confidence in its existing product lineup amidst changing market conditions.
Sources
Every quote below is verbatim from the article it is attributed to.
“Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.”
CNBC — Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs“Pfizer Inc. raised the midpoint of its 2026 sales forecast after reporting strong second-quarter demand for older medicines.”
Bloomberg — Pfizer Raises Sales Guidance on High Demand for Older Drugs“Pfizer posted stronger earnings than expected and raised its revenue outlook”
quartz — Pfizer posted stronger earnings than expected and raised its revenue outlook
“Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat”
Yahoo Finance — Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat
Earlier versions
- Aug 4, 10:52 AM — Pfizer Raises Sales Guidance on Strong Demand for Older Drugs (1/1)